TY - JOUR
T1 - Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer
AU - Webber, Kate
AU - Friedlander, Michael L.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Chemotherapy plays a key role in the management of women with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Platinum- and taxane-based regimens are the standard of care for adjuvant treatment in early-stage EOC and first-line therapy for advanced stage disease. Efforts to define the optimal scheduling, timing and route of administration are ongoing. The majority of women with EOC will develop recurrent disease, and treatment options for these women are depend on the time that has elapsed from first-line therapy. Platinum-based doublet chemotherapy is preferred for women with platinum-sensitive recurrent cancer. In platinum-resistant relapsed EOC, options are much more limited, and careful consideration of symptoms, performance status, anticipated toxicity and quality of life is essential when recommending chemotherapy for these women.
AB - Chemotherapy plays a key role in the management of women with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Platinum- and taxane-based regimens are the standard of care for adjuvant treatment in early-stage EOC and first-line therapy for advanced stage disease. Efforts to define the optimal scheduling, timing and route of administration are ongoing. The majority of women with EOC will develop recurrent disease, and treatment options for these women are depend on the time that has elapsed from first-line therapy. Platinum-based doublet chemotherapy is preferred for women with platinum-sensitive recurrent cancer. In platinum-resistant relapsed EOC, options are much more limited, and careful consideration of symptoms, performance status, anticipated toxicity and quality of life is essential when recommending chemotherapy for these women.
KW - chemotherapy
KW - epithelial ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85008192385&partnerID=8YFLogxK
U2 - 10.1016/j.bpobgyn.2016.11.004
DO - 10.1016/j.bpobgyn.2016.11.004
M3 - Review Article
C2 - 28027849
SN - 1521-6934
VL - 41
SP - 126
EP - 138
JO - Best Practice and Research: Clinical Obstetrics and Gynaecology
JF - Best Practice and Research: Clinical Obstetrics and Gynaecology
ER -